AVIS, MICCAI 2025 Pathology AI Foundation Model Runner-up

Avis Proves Core Pathological AI Technology at World's Most Prestigious Academic Conference... Secures Global Competitive Advantage Avis, a specialized AI-based pathology analysis company, has been recognized for its unique AI technology on the world stage, establishing itself as a leader in the global pathological AI market. Avis's AI research team (Gunwoo Noh, Kyungtae Min, Changhyun Song) achieved the remarkable feat of securing a proud second place in the UNICORN Challenge, hosted by MICCAI 2025, the most authoritative international academic conference in the field of medical artificial intelligence. This achievement at MICCAI, where leading scholars in medical AI from around the world gather annually to exchange the latest technologies, holds significant meaning as it officially recognizes the excellence and versatility of Avis's self-developed 'foundation model' technology specialized for pathological images. In particular, the 'Pathology Vision' part of the UNICORN Challenge, where Avis secured second place, is a core area that intensively evaluates the versatility and generalization performance of AI models. This was a highly challenging task, competing on how accurately a single, general-purpose AI model could analyze vast pathological images across various organs, staining methods, and diseases that it had not been previously trained on, and how flexibly it could be applied to multiple tasks. Based on its years of accumulated pathological AI image analysis technology, Avis demonstrated outstanding accuracy and stable analysis performance on the unknown test dataset provided by the organizers, surpassing leading companies and university research teams worldwide. This award once again proves that Avis's capabilities extend beyond specific AI solutions, demonstrating world-class 'foundation model core technology' as its underlying strength. Powerful foundation model technology will serve as a core competitive advantage in the future development of various commercial AI solutions, enabling the rapid and efficient implementation of advanced specialized models for diagnosing various cancer types, predicting prognosis, and discovering biomarkers with minimal additional training. Lee Dae-hong, CEO of Avis, stated, "I am very proud that our research team's unique foundation model technology has been officially recognized at MICCAI, where world-renowned AI scholars gather." He added, "Building on this achievement, we will concentrate all our efforts on innovatively improving the accuracy and efficiency of pathological diagnosis and commercializing groundbreaking AI solutions that will change the paradigm of precision medicine."